PubMed Health⌕ Search

PubMed · 14437553

[Syncope, epilepsy, syncopal equivalents].

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M RISER, L GAYRAL, H STERN. 1959. [Syncope, epilepsy, syncopal equivalents].. https://pubmed.ncbi.nlm.nih.gov/14437553/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Long-term seizure outcomes and factors associated with response to adjunctive everolimus in TSC-associated epilepsy.

BACKGROUND: Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, is increasingly used in tuberous sclerosis complex (TSC)-associated epilepsy; however, long-term real-world outcomes and factors associated with favorable response remain unclear. This study aimed to evaluate the long-term seizure outcomes of adjunctive everolimus and explore clinical factors associated with treatment response. METHODS: We retrospectively recruited 21 patients with active TSC-associated epilepsy receiving adjunctive everolimus and assessed seizure outcomes during follow-up. Clinical characteristics were compared between responders and non-responders at 1 year after treatment initiation. RESULTS: Over a median treatment duration of 72 months, responder rates ranged from 53.8% to 64.7%, and seizure-free rates ranged from 33.3% to 41.2%. Responders had fewer involved organ systems at baseline (median 3 vs. 4, p = 0.020) and lower anti-seizure medication burden (median 2 vs. 4, p = 0.045). Younger age at treatment initiation showed a trend toward improved response. CONCLUSION: Adjunctive everolimus was associated with sustained long-term seizure reduction in this real-world cohort. In exploratory analyses, fewer involved organ systems and fewer baseline ASMs were associated with favorable treatment response. These findings require validation in larger prospective cohorts.

Epilepsy↗

The role of FDG-PET, ictal SPECT, and MEG in the epilepsy surgery evaluation.

2-[18F]Fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET), ictal single-photon-emission computed tomography (ictal SPECT), and magnetoencephalography (MEG) represent three established functional imaging tests that offer unique information toward the localization of epilepsy for surgery evaluation and treatment. When these tests are combined with high-resolution magnetic fresonance imaging (MRI), epilepsy related structure and function disturbances may be localized with a degree of confidence and understanding not possible with electroencephalography (EEG), even ictal recordings with intracranial electrodes, the mainstay of tools for seizure localization. Use of these alternative tests allows an increased percentage of patients to be considered for surgical treatment. In particular, the additional information provided by these techniques has been demonstrated to help those patients with nonlocalizing MRI or extratemporal lobe epilepsy. Studies that address optimal use of these tests (alone and in combination) will build toward the next major advancement in the surgical treatment of epilepsy by allowing better patient selection, less risk, and better surgical outcomes. Ultimately, appropriate use of these tests, combined with more comprehensive functional brain mapping (e.g., with MEG or functional MRI), may lead to completely noninvasive epilepsy surgery evaluation.

Epilepsy↗